Mice point to lymph nodes in Alzheimer’s-like brain damage

Two mouse brains sit at the center of a new clue about Alzheimer’s-like damage: one shows the tissue injury associated with tau buildup, while the other shows what happens when the harmful immune response is prevented. Researchers at Washington University School of Medicine in St. Louis found that removing dendritic cells from lymph nodes and other locations sharply reduced the neurodegeneration that normally develops in these mice.

The pathway begins outside the brain. Dendritic cells are immune cells that instruct T cells — defenders that attack cells carrying a recognized target — which molecular signals to pursue. In the mouse models, peripheral dendritic cells primed CD8 T cells, a subtype of T cell, and those cells accumulated in the brain after tau tangles had formed. The brain contains very few of the relevant dendritic cells, and the ones present did not appear to be directing this response.

The researchers’ intervention removed dendritic cells from lymph nodes and other locations. That wiped out the elevated T-cell levels in the brain and the accompanying damage, while leaving the amount of tau tangles unchanged. The mice also retained their cognitive abilities. The findings were published in Nature Neuroscience on Sept. 3, 2026, in a study of tau-mediated neurodegeneration.

Concretely, the result points drug developers toward immune targets that may be reachable without sending a medicine through the blood-brain barrier. T-cell manipulation has already been studied extensively, and some approaches are approved for other diseases, but none of that establishes an Alzheimer’s treatment here. The researchers still need to test whether blocking dendritic-cell activity in midlife — rather than from birth, as in this study — can slow damage.

The most important uncertainty is upstream: Holtzman says tau-related injury may release material that travels from the brain to lymph nodes in the neck, where dendritic cells flag it for T cells. That explanation remains a hypothesis. The team is now looking for the precise activating signal and the mechanism that guides T cells back to the brain; until those steps are identified and tested beyond mice, the finding is a therapeutic direction rather than a therapy.